Serum Interleukin-39 as an Emerging Inflammatory Biomarker in Diabetes Mellitus: Evidence from ROC Curve Analysis
DOI:
https://doi.org/10.64354/4nx8w333Keywords:
IL-39, T2DM, Diabetes mellitusAbstract
Background: Diabetes mellitus is related to chronic low-level inflammation that leads to metabolic perturbations. Interleukin (IL)-39 is a novel cytokine, but its involvement in the pathogenesis of inflammation and diabetes has yet to be clarified. Objective: To measure serum IL-39 level and evaluate the diagnostic value of IL-39 in patients with diabetes mellitus. Methods: It was a case–control study with diabetic patients and controls. Anthropometric, glycemic, lipid, and insulin resistance measurements were determined. Serum IL-39 was quantified, and the diagnostic accuracy was determined on the basis of receiver operating characteristic (ROC) curve analysis. Results: The levels of serum IL-39 were higher in the diabetic patients than those in healthy controls (P < 0.001). The detection performance of IL-39 in the diagnosis of diabetic patients was well evaluated by ROC curve analysis with a large area under the curve. Circulating IL-39 was positively correlated with markers of glycemic disturbance and insulin resistance.
References
Al-Samarrai, A. & Al-Taee, A., 2022. Elevated interleukin-39 levels in systemic lupus erythematosus: Implications for disease activity. Immunology Letters, 254, pp.12-18.
Bahgat, N. & Ibrahim, S., 2020. Inflammatory cytokines and metabolic parameters in diabetes mellitus: A review of conflicting findings. Diabetes Research and Clinical Practice, 165, p.108228.
Berlin, I., et al., 2000. Visceral adiposity and cytokine production: Implications for metabolic syndrome. Journal of Clinical Endocrinology & Metabolism, 85(12), pp.4560-4565.
Cerf, M.E., 2013. Beta cell dysfunction and apoptosis in type 2 diabetes. Journal of Endocrinology, 216(1), pp.T1-T15.
Donath, M.Y. & Shoelson, S.E., 2011. Type 2 diabetes as an inflammatory disease. Nature Reviews Immunology, 11(2), pp.98-107.
El-Sayed, N., et al., 2024. Interleukin-39 and metabolic inflammation in obese type 2 diabetic patients. Cytokine, 148, p.155798.
Goldberg, I.J., 2001. Diabetic dyslipidemia: Causes and consequences. Journal of Clinical Endocrinology & Metabolism, 86(3), pp.965-971.
Hassan, R., et al., 2024. IL-39 levels in diabetic patients with periodontitis: A marker of chronic inflammation. Journal of Diabetes and Its Complications, 38(1), p.107994.
International Diabetes Federation (2021) IDF Diabetes Atlas, 10th edn. Brussels: International Diabetes Federation. Available at: https://diabetesatlas.org/ (Accessed: 15 January 2026).
Kontush, A. & Chapman, M.J., 2006. Functionally defective high-density lipoprotein: A new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacological Reviews, 58(3), pp.342-374.
Li, X., et al., 2022. The role of interleukin-39 in autoimmune diseases: A systematic review. Autoimmunity Reviews, 21(6), p.102983.
Lu, Y., et al., 2020. IL-39 as a novel cytokine in chronic inflammatory diseases with metabolic involvement. Frontiers in Immunology, 11, p.1234.
Majeed, A., et al., 2022. Relationship between glycemic control and inflammatory markers in type 2 diabetes. Clinical Biochemistry, 98, pp.32-38.
Mooradian, A.D., 2009. Dyslipidemia in type 2 diabetes mellitus. Nature Clinical Practice Endocrinology & Metabolism, 5(3), pp.150-159.
Nussrat, S. & Ad’hiah, A.H., 2023. Serum IL-39 levels and obesity-related inflammation in type 2 diabetes. Cytokine, 157, p.155912.
Taylor-Fishwick, D.A., et al., 2013. IL-12 family cytokines impair insulin secretion through beta-cell apoptosis. Endocrinology, 154(4), pp.1502-1511.
Wang, C., et al., 2016. IL-39 promotes inflammatory signaling via STAT1/STAT3 activation. Journal of Immunology, 196(7), pp.3020-3029.
Wang, Y., et al., 2021. Mechanisms of IL-39 in pro-inflammatory responses and metabolic diseases. Cytokine & Growth Factor Reviews, 58, pp.36-45.
Weaver, C.T., et al., 2015. The IL-12 cytokine family and metabolic disease: JAK/STAT signaling insights. Trends in Endocrinology & Metabolism, 26(5), pp.273-283.
Zhang, L., et al., 2020. Challenges in detecting IL-39 in human immune responses. Immunology, 159(3), pp.234-241.
Zhang, X., et al., 2023. Diagnostic potential of serum IL-39 in type 2 diabetes mellitus. Diabetes & Metabolism, 49(1), p.101484.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Chemical Interactions
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
